Amicus Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	598.7	528.3	399.36	329.23	305.51	260.89
Revenue Growth (YoY)	21.28%	32.29%	21.30%	7.76%	17.11%	43.16%
Cost of Revenue	61.22	52.94	37.33	38.6	34.47	31.04
Gross Profit	537.49	475.35	362.03	290.63	271.05	229.84
Selling, General & Admin	353.07	323.38	275.27	213.04	192.71	156.41
Research & Development	142.29	109.36	152.38	276.68	272.05	308.44
Operating Expenses	502.97	441.29	435.52	495.06	470.97	473.7
Operating Income	34.52	34.06	-73.49	-204.43	-199.92	-243.85
Interest Expense	-46.69	-49.6	-50.15	-37.12	-32.47	-22.43
Interest & Investment Income	3.9	5.41	7.08	3.02	0.51	3.23
Other Non Operating Income (Expenses)	14.96	-9.44	-15.89	4.18	-2.9	-0.78
EBT Excluding Unusual Items	6.68	-19.57	-132.45	-234.35	-234.78	-263.83
Merger & Restructuring Charges	-	-9.19	-	-	-	-
Asset Writedown	-1.7	-	-1.13	-6.62	-	-
Other Unusual Items	-	-	-16.52	-1.08	-6.77	-10.42
Pretax Income	4.98	-28.76	-150.1	-242.04	-241.55	-274.25
Income Tax Expense	19.04	27.35	1.48	-5.47	8.91	2.6
Net Income	-14.06	-56.11	-151.58	-236.57	-250.46	-276.85
Net Income to Common	-14.06	-56.11	-151.58	-236.57	-250.46	-276.85
Shares Outstanding (Basic)	308	304	295	289	271	259
Shares Outstanding (Diluted)	308	304	295	289	271	259
Shares Change (YoY)	1.52%	3.12%	2.11%	6.50%	4.85%	7.67%
EPS (Basic)	-0.05	-0.18	-0.51	-0.82	-0.92	-1.07
EPS (Diluted)	-0.05	-0.18	-0.51	-0.82	-0.92	-1.07
Free Cash Flow	9.69	-37.44	-76.53	-170.34	-206.38	-236.52
Free Cash Flow Per Share	0.03	-0.12	-0.26	-0.59	-0.76	-0.91
Gross Margin	89.78%	89.98%	90.65%	88.28%	88.72%	88.10%
Operating Margin	5.76%	6.45%	-18.40%	-62.09%	-65.44%	-93.47%
Profit Margin	-2.35%	-10.62%	-37.96%	-71.85%	-81.98%	-106.12%
Free Cash Flow Margin	1.62%	-7.09%	-19.16%	-51.74%	-67.55%	-90.66%
EBITDA	42.12	42.61	-65.62	-199.08	-193.71	-235.01
EBITDA Margin	7.03%	8.07%	-16.43%	-60.47%	-63.41%	-90.08%
D&A For EBITDA	7.6	8.55	7.87	5.34	6.21	8.85
EBIT	34.52	34.06	-73.49	-204.43	-199.92	-243.85
EBIT Margin	5.76%	6.45%	-18.40%	-62.09%	-65.44%	-93.47%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.